Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Alina Markova, MD, Memorial Sloan Kettering

Conference Coverage

Topical Ruxolitinib Shows Promise for Treatment of Patients With Chronic Cutaneous GVHD

01/11/2024

Featuring Alina Markova, MD

At the 65th ASH Annual Meeting in San Diego, California, Alina Markova, MD, shared study results that demonstrated ruxolitinib 1.5% cream was safe and effective compared to placebo in treating cutaneous nonsclerotic and superficially...

At the 65th ASH Annual Meeting...

01/11/2024

Oncology

Daniel Wolff, MD, University Hospital Regensburg

Conference Coverage

AGAVE-201 Trial Finds Axatilimab Yields Durable Responses for R/R Chronic GVHD Treatment

12/18/2023

Featuring Daniel Wolff, MD

At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...

At the 2023 ASH Annual Meeting...

12/18/2023

Oncology

Videos

Latest Updates in Graft-Versus-Host Disease Prophylaxis

11/13/2023

Featuring Shernan Holtan, MD

Shernan Holtan, MD, explores the most recent data in terms of graft-versus-host-disease prophylaxis.

Shernan Holtan, MD, explores the...

11/13/2023

Oncology

Videos

Frontline Treatment Options for Acute Graft-Versus-Host Disease

11/13/2023

Featuring Shernan Holtan, MD

Shernan Holtan, MD, explores advances and unmet needs in the frontline treatment of patients with acute graft-versus-host-disease.

Shernan Holtan, MD, explores...

11/13/2023

Oncology

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Natalizumab Plus Corticosteroid Regimen Ineffective in Improving Outcomes for Newly Diagnosed High-Risk GI GVHD

09/28/2023

Gina Tomaine

A regimen of natalizumab combined with corticosteroids was generally well-tolerated but did not improve outcomes for patients with newly diagnosed high-risk GI GVHD, according to a phase 2 study.

A regimen of natalizumab...

09/28/2023

Oncology

Quiz

Comparing Post-Transplantation Cyclophosphamide, Tacrolimus, Mycophenolate, and Mofetil with Standard Prophylaxis for Patients With GVHD

09/20/2023

True or False: A phase 3 trial comparing types of graft-versus-host-disease prophylaxis found that, for patients receiving reduced intensity conditioning, post-transplantation cyclophosphamide, mycophenolate, mofetil, and tacrolimus offered...

True or False: A phase 3 trial...

09/20/2023

Oncology

Videos

Exploring Mechanisms and Approaches for Graft-Versus-Host Disease Prophylaxis

09/05/2023

Featuring Ernst Holler, MD

Ernst Holler, MD, provides insights and analyses regarding the latest mechanisms and approaches for graft-versus-host disease prophylaxis, explaining the latest evolution of T-cell interaction methods.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Analyzing Risk Factors for Acute and Chronic Graft-Versus-Host Disease

09/05/2023

Featuring Ernst Holler, MD

Ernst Holler, MD, provides expert insights into the latest data on risk factors for the development of acute and chronic graft-versus-host disease.

Ernst Holler, MD, provides...

09/05/2023

Oncology

Videos

Outcomes of Patients Treated With Abatacept for the Prevention of GVHD

08/22/2023

Featuring Benjamin Watkins, MD

Featuring Benjamin Watkins, MD ...

Benjamin Watkins, MD, provides insights into the latest research regarding patients treated with immunomodulator abatacept for the prevention of graft-versus-host disease.

Benjamin Watkins, MD, provides...

08/22/2023

Oncology

Recent News

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology